Patients who had DDX11-positive and TMEM38B-negative tumors had significantly higher chances of cancer-specific death (odds ratio [OR] 49.000; 95% confidence interval [CI] 3.765–637.794) and recurrence (OR 28.000, 95% CI 2.399–326.735; Table 4 and Table S4). Here, DDX11 is linked to cancer.